Duke Comprehensive Cancer Center :: The Promise of Research

Trial	Phase	Pediatric Sarcomas (Sorted by Stage)

00001189	III	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) ARST0531
00001918	III	ARST0332 Risk Based Treatment for Pediatric Non-Rhabdomysarcoma Soft Tissue Sarcomas (NRSTS)
00005776	II	COG AOSTO221: A Phase II Study of Aerosolized GM-CSF (NSC#613795, IND 11042) in Osteosarcoma Patients with First Pulmonary Recurrence of Osteosarcoma
00008598	II	COG ARST0321: Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy.
00006597	III	COG ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
00004533	II	COG ARST0121: A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination with Vincristine and Pilot Assessment of Safety and Efficacy of Tirapazamine Combined with Multiagent CT for First Relapse or Progressive D